Advertisement

Mechanisms of resistance against B-cell malignancies induced by vaccination against the immunoglobulin receptor: the case for T-cell immunity

  • Lars A. Sternas
  • Steve W. Weeks
  • Larry W. Kwak
Part of the Cancer Treatment and Research book series (CTAR, volume 99)

Abstract

Immunoglobulin (Ig) molecules are composed of heavy and light chains that possess highly variable regions at their amino termini. These variable regions combine to form the antigen recognition site, which can itself be recognized as an antigen, termed the idiotype. B-cell malignancies are clonal proliferations of Ig-producing cells. The idiotypic determinants of the surface Ig can thus serve as a tumor-specific marker for the malignant clone. We and others continue to investigate strategies to induce specific immunity against the idiotypic determinants on the Ig molecule expressed and/or secreted by B-cell malignancies by active immunization. This chapter will summarize the progress in exploiting tumor-derived Ig protein as a tumor-specific antigen for therapeutic vaccine development and the priorities for future investigation.

Keywords

Keyhole Limpet Hemocyanin Myeloma Protein MOPC Tumor Antigen Recognition Site Idiotypic Determinant 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sirisinha S, Eisen N. 1971. Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins. Proc Natl Acad Sci USA 68:3130–3135.PubMedCrossRefGoogle Scholar
  2. 2.
    Lynch RG, Graff RJ, Sirisinha S, Simms ES, Eisen HN. 1972. Myeloma proteins as tumor-specific transplantation antigens. Proc Natl Acad Sci USA 69:1540–1544.PubMedCrossRefGoogle Scholar
  3. 3.
    Hannestad K, Kao M-S, Eisen HN. 1972. Cell-bound myeloma on the surface of myeloma cells: potential targets for the immune system. Proc Natl Acad Sci USA 69:2295.PubMedCrossRefGoogle Scholar
  4. 4.
    Jorgensen T, Gaudernack G, Hannestad K. 1980. Immunization with the light chain and the VL domain of the isologous myeloma protein 315 inhibits growth of mouse plasmacytoma MOPC315. Scand J Immunol 11:29–35.PubMedCrossRefGoogle Scholar
  5. 5.
    Sugai S, Palmer DW, Talal N, Witz IP. 1974. Protective and cellular immune responses to idiotypic determinants on cells from a spontaneous lymphoma of NZB/NZW F1 mice. J Exp Med 140:1547–1558.PubMedCrossRefGoogle Scholar
  6. 6.
    George AJT, Tutt AL, Stevenson FK. 1987. Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma BCL1. J Immunol 138:628–634.PubMedGoogle Scholar
  7. 7.
    Kaminski MS, Kitamura K, Maloney DG, Levy R. 1987. Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free Idiotype protein. J Immunol 138:1289–1296.PubMedGoogle Scholar
  8. 8.
    Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R. 1990. Idiotype vaccination against murine B cell lymphoma: humoral and cellular requirements for the full expression of anti-tumor immunity. J Immunol 145:1029–1036.PubMedGoogle Scholar
  9. 9.
    Lauritzsen GF, Weiss S, Bogen B. 1993. Anti-tumor activity of idiotype-specific MHC-restricted Th1 and Th2 clones in vitro and in vivo. Scand J Immunol 37:77.PubMedCrossRefGoogle Scholar
  10. 10.
    Lauritzsen GF, Weiss S, Dembic Z, Bogen B. 1994. Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors. Proc Natl Acad Sci USA 91:5700–5704.PubMedCrossRefGoogle Scholar
  11. 11.
    Lauritzsen GF, Bogen B. 1993. The role of idiotype-specific, CD4+ T cells in tumor resistance against major histocompatibility complex class II molecule negative plasmacytoma cells. Cell Immunol 148:177.PubMedCrossRefGoogle Scholar
  12. 12.
    Cao W, Myers-Powell BA, Braciale TJ. 1994. Recognition of an immunoglobulin VH epitope by influenza virus-specific class I major histocompatibility complex-restricted cytolytic T lymphocytes. J Exp Med 179:195–202.PubMedCrossRefGoogle Scholar
  13. 13.
    Kwak LW, Young HA, Pennington RW, Weeks SW. 1996. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci USA 93:10972–10977.PubMedCrossRefGoogle Scholar
  14. 14.
    Kawamura H, Rosenberg SA, Berzofsky JA. 1985. Immunization with antigen and interleukin 2 in vivo overcomes Ir gene low responsiveness. J Exp Med 162:381.PubMedCrossRefGoogle Scholar
  15. 15.
    Nunberg JH, Doyle MV, York SM, York CJ. 1989. Interleukin-2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine. Proc Natl Acad Sci USA 86:4240.PubMedCrossRefGoogle Scholar
  16. 16.
    Playfair JHL, DeSouza JB. 1987. Recombinant gamma interferon is a potent adjuvant for a malaria vaccine in mice. Clin Exp Immunol 67:5.PubMedGoogle Scholar
  17. 17.
    Staruch MJ, Wood DD. 1983. The adjuvanticity of interleukin 1 in vivo. J Immunol 130:2191.PubMedGoogle Scholar
  18. 18.
    McCune GS, Marquis DM. 1990. Interleukin 1 as an adjuvant for active-specific immuno-therapy in a murine tumor model. Cancer Res 50:1212.PubMedGoogle Scholar
  19. 19.
    Kwak LW, Campbell MJ, Czerwinski D, Hart S, Miller RA, Levy R. 1992. Induction of immune responses in patients with B-cell lymphoma against the surface immunoglobulin idiotype expressed by their tumors. N Engl J Med 327:1209–1215.PubMedCrossRefGoogle Scholar
  20. 20.
    Sternas L, Janik JE, Duffey PL, Gocke C, Reynolds CW, Wittes RE, Kwak LW. 1996. Early results of a clinical trial of therapeutic vaccination with Ig idiotype antigen for de novo follicular lymphoma. Blood 88(Suppl l):672a. (abstract)Google Scholar
  21. 21.
    Kwak LW, Taub DD, Duffey PL, Bensinger WI, Bryant EM, Reynolds CW, Longo DL. 1995. Transfer of myeloma idiotype-specific immunity from an actively immunized marrow donor. Lancet 345:1016–1020.PubMedCrossRefGoogle Scholar
  22. 22.
    Tao M-H, Levy R. 1993. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362:755.PubMedCrossRefGoogle Scholar
  23. 23.
    Hawkins RE, Winter G, Hamblin TJ, Stevenson FK, Russell SJ. 1993. A genetic approach to idiotypic vaccination. J Immunother 14:273–278.CrossRefGoogle Scholar
  24. 24.
    Syrengelas AD, Chen TT, Levy R. 1996. DNA immunization induces protective immunity against B-cell lymphoma. Nature Med 2:1038–1041.PubMedCrossRefGoogle Scholar
  25. 25.
    Levitsky HI, Montgomery J, Ahmadzadeh M, Staveley-O’Carroll K, Guarnieri F, Longo DL, Kwak LW. 1996. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-l-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J Immunol 156:3858–3865.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers, Boston 1999

Authors and Affiliations

  • Lars A. Sternas
  • Steve W. Weeks
  • Larry W. Kwak

There are no affiliations available

Personalised recommendations